{'fraction_non_alphanumeric': 0.02967032967032967, 'fraction_numerical': 0.04285714285714286, 'mean_word_length': 6.23015873015873, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preoperative management of antithrombotic medication in Mohs micrographic surgery.

© 2015 The Authors. doi: 10.2340/00015555-2090 Journal Compilation © 2015 Acta Dermato-Venereologica. ISSN 0001-5555 Many patients presenting for dermatologic surgery use antithrombotic medication. It remains controversial whether or not this medication should be withheld prior to cutaneous surgery. Different studies, including one meta-analysis, have assessed the risk of bleeding when antithrombotic medication was continued and showed conflicting results (1–8). Furthermore, case reports illustrated the potential life-threatening risk of temporary discontinuation of antithrombotic medication (9–11). We evaluated the frequency of postoperative haemorrhage and thrombotic events in patients continuing their antithrombotic medication with those temporarily withholding this medication prior to Mohs micrographic surgery.